Back to News
Market Impact: 0.42
Adarx Pharmaceuticals Raises $446.3 Million in Upsized US IPO
Source: Bloomberg
IPOs & SPACsHealthcare & BiotechCompany Fundamentals
Adarx Pharmaceuticals raised $446.3 million in an upsized IPO, with the offering priced at the top of its marketed range. The strong fundraising outcome signals robust investor demand for the late-stage gene-therapy developer and is likely supportive for biotech IPO market sentiment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.58
More News
- Jensen Huang’s $21 billion net worth in AI rout—Nvidia’s recovery will be ‘capped’ after he admitted affair with alleged Chinese spy
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- Weekend trading of Nvidia scandal shines light on new financial products
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- AI for Investment Thesis Validation: A Claim-Ledger Method
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)